Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

BMO Capital lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 and keeps an Outperform rating on the shares. The shares are ...

Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...

NEW YORK (AP) — NEW YORK (AP) — Neurogene Inc. (NGNE) on Monday reported a loss of $20.2 million in its third quarter. The New York-based company said it had a loss of $1.19 per share. The results ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...

Neurogene reported a patient experienced systemic hyperinflammatory syndrome during their Rett syndrome gene therapy trial. CEO Rachel McMinn confirmed the female patient is in critical condition. The ...

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.